vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ESSENTIAL PROPERTIES REALTY TRUST, INC. (EPRT). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $158.8M, roughly 1.6× ESSENTIAL PROPERTIES REALTY TRUST, INC.). ESSENTIAL PROPERTIES REALTY TRUST, INC. runs the higher net margin — 37.8% vs 11.1%, a 26.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 22.8%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 20.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Essential Properties Realty Trust is a publicly traded real estate investment trust (REIT) that acquires, owns and manages a diversified portfolio of single-tenant net-leased commercial properties across the United States. Its assets primarily cover essential service-oriented sectors including casual dining, automotive services, medical clinics, early childhood education centers and light industrial facilities, with tenants mostly holding robust long-term operating track records.
ANIP vs EPRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $158.8M |
| Net Profit | $27.5M | $60.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 56.5% |
| Net Margin | 11.1% | 37.8% |
| Revenue YoY | 29.6% | 22.8% |
| Net Profit YoY | 367.5% | 6.5% |
| EPS (diluted) | $1.14 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $158.8M | ||
| Q4 25 | $247.1M | $149.9M | ||
| Q3 25 | $227.8M | $144.9M | ||
| Q2 25 | $211.4M | $137.1M | ||
| Q1 25 | $197.1M | $129.4M | ||
| Q4 24 | $190.6M | $119.7M | ||
| Q3 24 | $148.3M | $117.1M | ||
| Q2 24 | $138.0M | $109.3M |
| Q1 26 | — | $60.0M | ||
| Q4 25 | $27.5M | $68.1M | ||
| Q3 25 | $26.6M | $65.6M | ||
| Q2 25 | $8.5M | $63.2M | ||
| Q1 25 | $15.7M | $56.1M | ||
| Q4 24 | $-10.3M | $55.4M | ||
| Q3 24 | $-24.2M | $49.1M | ||
| Q2 24 | $-2.3M | $51.5M |
| Q1 26 | — | 56.5% | ||
| Q4 25 | 14.1% | 65.9% | ||
| Q3 25 | 15.9% | 64.7% | ||
| Q2 25 | 6.6% | 64.1% | ||
| Q1 25 | 13.3% | 61.6% | ||
| Q4 24 | -2.3% | 66.1% | ||
| Q3 24 | -13.8% | 59.7% | ||
| Q2 24 | 3.7% | 61.1% |
| Q1 26 | — | 37.8% | ||
| Q4 25 | 11.1% | 45.4% | ||
| Q3 25 | 11.7% | 45.3% | ||
| Q2 25 | 4.0% | 46.1% | ||
| Q1 25 | 8.0% | 43.4% | ||
| Q4 24 | -5.4% | 46.3% | ||
| Q3 24 | -16.3% | 42.0% | ||
| Q2 24 | -1.7% | 47.1% |
| Q1 26 | — | $0.28 | ||
| Q4 25 | $1.14 | $0.34 | ||
| Q3 25 | $1.13 | $0.33 | ||
| Q2 25 | $0.36 | $0.32 | ||
| Q1 25 | $0.69 | $0.29 | ||
| Q4 24 | $-0.45 | $0.31 | ||
| Q3 24 | $-1.27 | $0.27 | ||
| Q2 24 | $-0.14 | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $15.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $4.4B |
| Total Assets | $1.4B | $7.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $15.2M | ||
| Q4 25 | $285.6M | $60.2M | ||
| Q3 25 | $262.6M | $23.8M | ||
| Q2 25 | $217.8M | $20.8M | ||
| Q1 25 | $149.8M | $47.0M | ||
| Q4 24 | $144.9M | $40.7M | ||
| Q3 24 | $145.0M | $32.7M | ||
| Q2 24 | $240.1M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $1.9B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $540.7M | $4.2B | ||
| Q3 25 | $505.8M | $3.8B | ||
| Q2 25 | $436.8M | $3.8B | ||
| Q1 25 | $418.6M | $3.8B | ||
| Q4 24 | $403.7M | $3.6B | ||
| Q3 24 | $405.9M | $3.2B | ||
| Q2 24 | $455.8M | $3.2B |
| Q1 26 | — | $7.2B | ||
| Q4 25 | $1.4B | $6.9B | ||
| Q3 25 | $1.4B | $6.6B | ||
| Q2 25 | $1.3B | $6.3B | ||
| Q1 25 | $1.3B | $6.1B | ||
| Q4 24 | $1.3B | $5.8B | ||
| Q3 24 | $1.3B | $5.5B | ||
| Q2 24 | $920.8M | $5.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $381.1M | ||
| Q3 25 | $44.1M | $99.0M | ||
| Q2 25 | $75.8M | $99.8M | ||
| Q1 25 | $35.0M | $77.2M | ||
| Q4 24 | $15.9M | $308.5M | ||
| Q3 24 | $12.5M | $73.5M | ||
| Q2 24 | $17.4M | $81.1M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 5.60× | ||
| Q3 25 | 1.66× | 1.51× | ||
| Q2 25 | 8.87× | 1.58× | ||
| Q1 25 | 2.23× | 1.38× | ||
| Q4 24 | — | 5.57× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | 1.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
EPRT
| Rental revenue 1,2 | $149.4M | 94% |
| Other | $8.6M | 5% |
| Other revenue | $779.0K | 0% |
